competitor analysis: cd20 antibodies 2015 - biosimilars and biosuperiors of rituximab
TRANSCRIPT
www.MarketResearchReports.com
Competitor Analysis: CD20
Antibodies 2015 - Biosimilars and Biosuperiors of
Rituximab
Category : Biotechnology
All logos and Images mentioned on this slide belong to their respective owners.
www.MarketResearchReports.com
Introduction to Report
Launch Date: March 25, 2015
Number of Pages: 62
Geography Coverage: Global
Available Format: PDF
Price For Single User License: USD 346
Price For Site User License: USD 692
Price For Global User License: USD 1,038
Delivery Time: Within 24 Hours (During Working Days)
www.MarketResearchReports.com
About the Report
This Competitive Intelligence Report about CD20 Antibodies 2015- Biosimilars and Biosuperiors of Rituximab provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated malignancies and rheumatoid arthritis as of March 2015.
www.MarketResearchReports.com
Key Highlights:
The chimeric anti-CD20 antibody rituximab (Rituxan / MabThera) from Biogen Idec and Roche is one of the world’s commercially most successful antibodies (2014 sales of over US$ 6.9 bln).
The commercial attractiveness of rituximab has stimulated companies to create and develop next generation anti-CD20 monoclonal antibodies with improved properties compared with the chimeric antibody rituximab.
www.MarketResearchReports.com
Key Highlights Continues…
The forthcoming patent expiry for Rituxan / MabThera has boosted interest in and activties for developing biosimilar copies with the most advanced projects already approved and marketed in less regulated countries, but also in phase III studies in Western regulated markets.
The report includes a compilation of currently active projects in development of CD20 targeting antibodies for treatment of hematologic malignancies and rheumatoid arthritis and other autoimmune diseases.
www.MarketResearchReports.com
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices.
The information is provided in a tabular format and fully referenced.
www.MarketResearchReports.com
The report includes format providing information on: Drug Codes,
Target / Mechanism of Action,
Class of Compound,
Company,
Product Category,
Indication,
R&D Stage and
additional comments with a hyperlink leading to the source of information.
www.MarketResearchReports.com
Report Coverage:
1. CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab
2. 2014 Sales of CD20 Antibodies
3. Marketed CD20 Antibodies & Sales
4. Biosuperior CD20 Antibodies
5. Biosimilar CD20 Antibodies
6. Corporate CD20 Antibody Biosimilar & Biosuperior Pipelines
For more details regarding Report coverage see the last slide
www.MarketResearchReports.com
Custom Research: Are you an industry professional, entrepreneur,
venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research.
For Any Customization Related query Visit IdeaCenter @http://www.marketresearchreports.com/idea-center
For regular industry updates subscribe to our newsletter at: http://www.marketresearchreports.com/subscribe-to-newsletter
www.MarketResearchReports.com
How To Buy This Report?
Visit following URL to see Table of Content and purchase this publication:
http://mrr.cm/4gk
About Market Research Reports, Inc.Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”.
Contact : Amitava SenEmail : [email protected]: +1 302-703-7787 (USA) +91-8762746600 (India)